Updated on 21 September 2015
Shire has recieved European Commission approval for ADHD drug
Singapore: Global pharmaceutical company, Shire, has recieved European Commission approval for INTUNIV (guanfacine hydrochloride prolonged release tablets) for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents.
"The approval of INTUNIV marks a significant advance in the treatment of ADHD in children and adolescents in Europe. Previously, physicians had only one licensed non-stimulant option for these patients," said Perry Sternberg, senior vice president, Neuroscience Business Unit, Shire.
"The importance of simply providing physicians with the ability to choose the non-stimulant option that may best suit the needs of their patients should not be overlooked, considering the complexities and different manifestations of the disorder in children and adolescents," he said.
ADHD is a common psychiatric disorder in children and adolescents and is recognised by the World Health Organization (WHO).